I make a donation

ADRIFT

Searching the rivaroxaban dosis which enables an adequate anticoagulation evaluated by the level of thrombin generated in patients suffering atrial fibrillation and having a successful percutaneous left atrial appendage closure.

Terminée

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

objectif

Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure

date de réalisation

2017

nombre de patients

nombre de centres participants

National multicentric trial

type de financement

Privé (Fonds de Dotation Action & Bayer)

Référence

NCT03273322

A study conducted by Fonds de Dotation ACTION
Find out details and results on the dedicated page

En cours

Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.

En cours

To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.

En cours

Phase 4 trial, evaluating the interest of betablocking treatment in the long term treatment of non-complicated myocardial infarct.